Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

OSTEOSARCOMA OF THE HUMERUS – A SINGLE INSTITUTION EXPERIENCE WITH 67 PATIENTS



Abstract

Besides the femur and the tibia, the humerus is the third most common localisation of osteosarcoma. 78 patients with osteosarcoma of the humerus have been treated at our institution since 1934. Among these, 7 patients have been admitted before implementation of the Vienna Tumour Registry in 1968, additionally 4 patients had undergone primary surgical resection at another institution. This left 67 patients for follow-up after multi-modal therapy of humeral osteosarcoma comprising neo-adjuvant and adjuvant chemotherapy and surgical resection. (38 males and 29 females with an average age of 21.8 years, range 3.6 to 73.2 years) The subtypes of tumours observed were classic osteosarcoma in 56 patients, parostal sarcoma in 4, teleangiectatic sarcoma in 3, secondary sarcoma in 2 (one in Morbus Paget and one after radiation of a hemangioendothelioma), high-grade surface sarcoma in 1 and a humeral lesion within a multifocal osteosarcoma in 1. The localisation was foremost the proximal humerus (61) and rarely affecting the distal (5) or total bone (1). 11 patients suffered from pulmonary metastases upon primary diagnosis. In 9 cases resection alone was indicated. 9 patients underwent a resection-replantation-plasty, and in 2 patients primary amputation was performed. 46 patients were treated by resection and endoprosthetic reconstruction using ceramic prostheses (7), custom-made endoprostheses (13) or humeral HMRS modular prostheses (26). Before 1980 a non-standardised neo-adjuvant and adjuvant chemotherapy was administered in 12 patients, all patients thereafter received a chemotherapeutic regimen according to the COSS or EURAMOS-1 protocol. In 3 patients with parostal sarcoma no adjuvant therapy was indicated. The patient with multifocal osteosarcoma was treated conservatively by chemotherapy, radiation and immunotherapy by dendritic cell vaccination. The overall survival was 58% at 5 years. 23 patients died of their disease at an average of 25 months after operation (range 2 to 135 months). Average follow-up of the remaining patients was 91 months. (range 1 to 389 months). 4 patients treated before 1982 developed local tumour recurrence leading to secondary amputation in all cases, and death of disease within 12 months in 3 cases, respectively. 16 patients had to undergo one or more revisions, including secondary amputation in 2. Pulmonary metastases were observed in 15 patients, 2 patients developed skeletal metastates. After resection of metastatses, 14 patients died of disease, among them 9 patients died within 12 months after operation. Upon latest follow-up, 3 patients were alive disease-free, the patient with multifocal osteosarcoma was alive with disease 22 months after primary diagnosis. The multimodal treatment of osteosarcoma shows satisfactory oncological results. The implementation of standardised chemotherapeutic protocols has improved overall outcome.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org